Cited by 117Chronic Obstructive Pulmonary Disease (COPD) ResearchAntioxidant Activity and Oxidative StressRedox biology and oxidative stress

Pharmacological antioxidant strategies as therapeutic interventions for COPD

Open access
Rahman, Irfan·2012·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Abstract

Cigarette/tobacco smoke/biomass fuel-induced oxidative and aldehyde/carbonyl stress are intimately associated with the progression and exacerbation of chronic obstructive pulmonary disease (COPD). Therefore, targeting systemic and local oxidative stress with antioxidants/redox modulating agents, or boosting the endogenous levels of antioxidants are likely to have beneficial effects in the treatment/management of COPD. Various antioxidant agents, such as thiol molecules (glutathione and mucolytic drugs, such as N-acetyl-L-cysteine and N-acystelyn, erdosteine, fudosteine, ergothioneine, and carbocysteine), have been reported to modulate various cellular and biochemical aspects of COPD. These antioxidants have been found to scavenge and detoxify free radicals and oxidants, regulate of glutathione biosynthesis, control nuclear factor-kappaB (NF-kappaB) activation, and hence inhibiting inflammatory gene expression. Synthetic molecules, such as specific spin traps like α-phenyl-N-tert-butyl nitrone, a catalytic antioxidant (ECSOD mimetic), porphyrins (AEOL 10150 and AEOL 10113), and a superoxide dismutase mimetic M40419, iNOS and myeloperoxidase inhibitors, lipid peroxidation inhibitors/blockers edaravone, and lazaroids/tirilazad have also been shown to have beneficial effects by inhibiting cigarette smoke-induced inflammatory responses and other carbonyl/oxidative stress-induced cellular alterations. A variety of oxidants, free radicals, and carbonyls/aldehydes are implicated in the pathogenesis of COPD, it is therefore, possible that therapeutic administration or supplementation of multiple antioxidants and/or boosting the endogenous levels of antioxidants will be beneficial in the treatment of COPD. This review discusses various novel pharmacological approaches adopted to enhance lung antioxidant levels, and various emerging beneficial and/or prophylactic effects of antioxidant therapeutics in halting or intervening the progression of COPD. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbadis.2011.11.004

Cites

190 of 190 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ERG has been found to be an effective antioxidant in cardiovascular diseases, chronic pulmonary diseases, lung inflammatory diseases, and other pathologies.

    “ERG has been found to be an effective antioxidant in cardiovascular diseases (Servillo et al. 2017), chronic pulmonary diseases (Rahman 2012), lung inflammatory diseases (Repine and Elkins 2012), and other pathologies.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

3 retracted

Flagged first, then by citations

2 of the 192 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. [144]Ishibashi Y Okamura T Masumoto Y Tachiiri T Momo K [Effects of carbocisteine on airway inflammation and related events in SO2-exposed rats] Nihon Kokyuki Gakkai Zasshi 2001 39 17 23 11296380
  2. [158]Nagaoka S Takishima T Nagano H Kawakami Y Kitamua S Kawakami M Ogura T Sasaki T Ogawa N Phase III Clinical Study of SS320A. Double-blind Trial in Comparison with Placebo Journal of Clinical Therapeutics & Medicines 2002 18 109 140

Cited by

Sorted by citations

Authors
Rahman, I.
Affiliations
University of Rochester Medicine (US)
Corresponding author
Rahman, Irfan
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Publisher
Elsevier BV
Published
2012-05
Volume
1822
Issue
5
Pages
714-728
ISSN
0925-4439 (ISSN-L)
OpenAlex
W2123397711
Cited by
117
References
192
Citations by year
2026: 3 · 2025: 2 · 2024: 7 · 2023: 10 · 2022: 8 · 2021: 10 · 2020: 3 · 2019: 6 · 2018: 9 · 2017: 10 · 2016: 8 · 2015: 8 · 2014: 16 · 2013: 10 · 2012: 7
FWCI
1.66
Type
journal article
Language
en
Open access
Locations
  • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders
  • National Institutes of Health (5r01hl097751-04, ES01247, 1R01HL097751)
  • National Heart, Lung, and Blood Institute (1R01HL097751, R01HL092842, R01-HL097751, R01HL085613)
  • National Institute of Environmental Health Sciences (ES-01247, P30ES001247)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Biochemistry › Antioxidant Activity and Oxidative Stress
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
Keywords
chronic obstructive pulmonary disease, antioxidants, oxidative stress, carbonyl stress, thiols, glutathione, N-acetylcysteine, erdosteine, ergothioneine, carbocysteine, spin traps, superoxide dismutase mimetic, porphyrins, edaravone, lazaroids, tirilazad, NF-κB, inflammation, cigarette smoke, biomass fuel, lipid peroxidation, antioxidant therapeutics
MeSH terms
Antioxidants, Humans, Pulmonary Disease, Chronic Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review